CagriSema
A once-weekly injection that combines two powerful appetite-suppressing drugs — cagrilintide and semaglutide — into a single shot. By targeting two different hunger pathways in the brain simultaneously, it achieves roughly 25% body weight loss in trials, making it one of the most effective weight loss treatments ever developed. Think of it as the next generation beyond Wegovy. Still awaiting FDA approval.
Dosage
Cagrilintide 2.4 mg + semaglutide 2.4 mg subcutaneous once weekly
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Administration
Subcutaneous injection (weekly, single pen)
Shop Research-Grade Peptides
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Weight Loss
Approximately 25% body weight loss in Phase 3 — among the highest for any pharmaceutical.
Appetite Suppression
Dual amylin + GLP-1 pathways target both hunger and meal size simultaneously.
Blood Sugar Control
Combined insulinotropic effects from two independent receptor populations.
Mechanism of Action
CagriSema exploits the principle that the brain's appetite regulation system has multiple independent signaling pathways, and targeting two of them simultaneously produces weight loss greater than either alone. The semaglutide component activates GLP-1 receptors in the hypothalamic arcuate nucleus and brainstem, suppressing hunger through POMC neuron activation and NPY/AgRP neuron inhibition, while also slowing gastric emptying and improving glycemic control.
The cagrilintide component activates amylin receptors (CTR/RAMP complexes) in the area postrema and lateral parabrachial nucleus — brain regions that form a parallel but distinct satiety circuit. Amylin receptor signaling reduces meal size by promoting early satiation, whereas GLP-1 signaling primarily reduces between-meal hunger and food cravings. Together, they address both the desire to eat and the amount consumed per meal.
At the metabolic level, both components enhance insulin secretion and suppress glucagon in a glucose-dependent manner, but through separate pancreatic receptor populations. The combination also produces synergistic effects on gastric emptying, further reducing postprandial glucose spikes. Phase 3 trial data showed approximately 25% body weight loss — among the highest recorded for any pharmaceutical intervention — with the combination significantly outperforming either component alone, validating the dual-pathway hypothesis.
Regulatory Status
Not yet FDA approved. Phase 3 trials completed. NDA submission expected 2025–2026. Novo Nordisk.
Risks & Safety
Common
nausea (30-45%), vomiting, diarrhea, constipation, reduced appetite, injection site reactions.
Serious
inflammation of the pancreas, gallstones, potential loss of muscle mass along with fat, heart safety still being studied.
Rare
thyroid tumour concern (animal studies), severe allergic reactions.
Compare CagriSema With
Research Papers
28Published: February 1, 2026
AI Summary
Bariatric surgery remains the most effective obesity treatment despite the rise of GLP-1 drugs. The review discusses how to improve both drug and surgery outcomes and argues that surgery will still play a key role alongside newer medications.
Published: December 15, 2025
AI Summary
In people who already have heart failure, higher body weight may be linked to better survival, while fitness and lean mass matter more than BMI. The review explores this paradox and its implications for obesity treatment in heart failure.
Published: December 9, 2025
AI Summary
A planned systematic review will compare semaglutide, tirzepatide, CagriSema, and liraglutide on hard cardiovascular outcomes across high-risk patients. CagriSema is not yet approved but is in phase III trials.
Published: November 23, 2025
AI Summary
GLP-1 drugs like liraglutide, semaglutide, and tirzepatide have transformed obesity treatment and may help in fatty liver, heart disease, and other conditions. The review outlines their promise and remaining hurdles.
Published: February 1, 2026
AI Summary
CagriSema significantly lowered blood pressure in adults with overweight or obesity in the REDEFINE 1 trial, alongside its known weight loss benefits.
Published: November 25, 2025
AI Summary
Combining GLP-1 with GIP, glucagon, amylin, or PYY can boost weight loss and metabolic benefits. Tirzepatide, CagriSema, and retatrutide lead this new class of multi-agonist drugs for obesity and diabetes.
Published: December 19, 2026
AI Summary
Amylin-based drugs may activate the renin-angiotensin system, but blood pressure still drops with CagriSema. The authors suggest that combining these drugs with ACE inhibitors or ARBs may enhance protective effects.
Published: October 6, 2025
AI Summary
New GLP-1-based drugs combine GLP-1 with GIP, glucagon, amylin, or PYY for stronger effects. CagriSema and amycretin are among the amylin-based options advancing toward approval.
Published: August 25, 2025
AI Summary
Incretin co-agonists like tirzepatide, CagriSema, and retatrutide are driving major advances in weight loss and cardiometabolic health. The review summarizes their mechanisms and clinical benefits.
Published: September 8, 2025
AI Summary
A new triple agonist targeting GLP-1, GIP, and Y2 receptors outperformed semaglutide and CagriSema in mice for weight loss and glucose control. The approach may lead to new obesity and diabetes treatments.
Published: November 25, 2025
AI Summary
New obesity drugs can achieve 15–25% weight loss, approaching bariatric surgery. CagriSema and other combinations are expected to reach similar weight loss to tirzepatide and retatrutide.
Published: July 7, 2025
AI Summary
CagriSema produced weight loss in rats mainly by reducing food intake, but about one-third of the effect came from preserving energy expenditure. This blunting of metabolic adaptation may help sustain weight loss.
Published: August 13, 2025
AI Summary
The study examined how well CagriSema promotes weight loss in adults with overweight or obesity and coexisting conditions.
Published: August 13, 2025
AI Summary
The trial evaluated CagriSema for weight management in adults with type 2 diabetes, including those using continuous glucose monitoring.
Published: June 6, 2025
AI Summary
Amylin helps control appetite and blood sugar but is low in people with diabetes. CagriSema, combining GLP-1 and amylin agonists, shows promise for both glucose and weight control.
Published: May 5, 2025
AI Summary
CagriSema is being studied as a safer option to lower blood sugar and body weight while reducing hypoglycemia risk. The article reviews diabetes management and the evidence for this combination.
Published: May 10, 2025
AI Summary
Incretin-based therapies like CagriSema and retatrutide are expanding beyond glucose and weight to liver, heart, and kidney benefits. The review covers developments from 2023 to early 2025.
Published: January 21, 2025
AI Summary
The obesity drug pipeline is growing rapidly, with CagriSema in phase 3 trials. Incretin-based drugs show the most promise, though more data on long-term safety and outcomes are needed.
Published: February 17, 2025
AI Summary
Amylin acts on multiple brain regions to reduce food intake. Understanding how cagrilintide and CagriSema affect these pathways may help optimize combination therapies for obesity.
Published: December 15, 2024
AI Summary
Cagrilintide did not prolong the heart’s electrical recovery (QT interval) in a thorough QT study, supporting its cardiac safety as part of CagriSema.
Published: October 23, 2024
AI Summary
Semaglutide reduced kidney and cardiovascular events in people with type 2 diabetes and kidney disease, whether or not they were taking SGLT2 inhibitors. Benefits were consistent across both groups.
Published: May 21, 2024
AI Summary
Oral GLP-1 drugs and injectable combinations like CagriSema are in development for type 2 diabetes and obesity. The review outlines where the field stands.
Published: February 28, 2025
AI Summary
CagriSema and retatrutide are in phase 3 trials and may achieve weight loss similar to or greater than tirzepatide. The review summarizes the obesity drug pipeline and what to expect.
Published: February 1, 2024
AI Summary
GLP-1 receptor medications are central to treating obesity and its health risks. The review explains their role and current use.
Published: January 28, 2024
AI Summary
The systematic review compared GLP-1 receptor agonists on blood sugar, weight, and lipids in type 2 diabetes.
Published: March 4, 2024
AI Summary
Semaglutide and tirzepatide have set new standards for diabetes and obesity treatment. CagriSema and retatrutide are among the next-generation options showing strong efficacy in trials.
Published: January 26, 2024
AI Summary
The review summarizes recent advances in polyagonist drugs for type 2 diabetes.
Published: August 25, 2023
AI Summary
CagriSema was tested for efficacy and safety in people with type 2 diabetes. The trial assessed its impact on weight and blood sugar control.
Frequently Asked Questions
What is CagriSema?
A once-weekly injection that combines two powerful appetite-suppressing drugs — cagrilintide and semaglutide — into a single shot. By targeting two different hunger pathways in the brain simultaneously, it achieves roughly 25% body weight loss in trials, making it one of the most effective weight loss treatments ever developed. Think of it as the next generation beyond Wegovy. Still awaiting FDA approval.
What is CagriSema used for?
A once-weekly injection that combines two powerful appetite-suppressing drugs — cagrilintide and semaglutide — into a single shot. By targeting two different hunger pathways in the brain simultaneously, it achieves roughly 25% body weight loss in trials, making it one of the most effective weight loss treatments ever developed. Think of it as the next generation beyond Wegovy. Still awaiting FDA approval.
What is the dosage for CagriSema?
Combination: cagrilintide 2.4 mg + semaglutide 2.4 mg subcutaneous once weekly. Dose escalation over 16 weeks, starting at lower doses of both components and increasing incrementally.
What are the side effects of CagriSema?
Common: nausea (30-45%), vomiting, diarrhea, constipation, reduced appetite, injection site reactions. Serious: inflammation of the pancreas, gallstones, potential loss of muscle mass along with fat, heart safety still being studied. Rare: thyroid tumour concern (animal studies), severe allergic reactions.
How does CagriSema work?
CagriSema exploits the principle that the brain's appetite regulation system has multiple independent signaling pathways, and targeting two of them simultaneously produces weight loss greater than either alone. The semaglutide component activates GLP-1 receptors in the hypothalamic arcuate nucleus and brainstem, suppressing hunger through POMC neuron activation and NPY/AgRP neuron inhibition, while also slowing gastric emptying and improving glycemic control. The cagrilintide component activates amylin receptors (CTR/RAMP complexes) in the area postrema and lateral parabrachial nucleus — brain regions that form a parallel but distinct satiety circuit. Amylin receptor signaling reduces meal size by promoting early satiation, whereas GLP-1 signaling primarily reduces between-meal hunger and food cravings. Together, they address both the desire to eat and the amount consumed per meal. At the metabolic level, both components enhance insulin secretion and suppress glucagon in a glucose-dependent manner, but through separate pancreatic receptor populations. The combination also produces synergistic effects on gastric emptying, further reducing postprandial glucose spikes. Phase 3 trial data showed approximately 25% body weight loss — among the highest recorded for any pharmaceutical intervention — with the combination significantly outperforming either component alone, validating the dual-pathway hypothesis.
How is CagriSema administered?
CagriSema is administered via subcutaneous injection (weekly, single pen).
What is the half-life of CagriSema?
The half-life of CagriSema is 168 hours (7 days) for both components.
Is CagriSema legal?
Not yet FDA approved. Phase 3 trials completed. NDA submission expected 2025–2026. Novo Nordisk.
Related Peptides
5-Amino-1MQ
A pill that aims to switch fat cells from 'storage mode' to 'burning mode' by blocking an enzyme (NNMT) that is overactive in the fat tissue of overweight people. Not technically a peptide, but commonly sold alongside them. Unlike appetite suppressants, this targets the fat cells directly rather than making you eat less. The science is promising in lab studies, but there are no completed human trials yet.
Adipotide
An extreme experimental approach to fat loss — it physically destroys the blood vessels that feed fat tissue, starving fat cells until they die. Originally developed using anti-cancer technology at MD Anderson Cancer Center. While it did reduce fat in monkey studies, it also caused serious kidney damage, which has effectively stopped its development. Not available for human use.
AOD-9604
A small piece of human growth hormone (amino acids 176-191) designed to keep only the fat-burning effects while removing the unwanted side effects of full growth hormone (like swelling and blood sugar problems). The idea is promising — burn fat without the downsides — but it failed to show significant weight loss in clinical trials. Still widely used in research and wellness clinics despite the weak clinical evidence.
Cagrilintide
A long-acting version of amylin, a natural hormone your body releases after eating that tells your brain you're full. It works through a completely different pathway than GLP-1 drugs like semaglutide, which is why combining them (as CagriSema) produces even better results. On its own, it reduces how much you eat per meal by signalling fullness earlier. Developed by Novo Nordisk, mainly as part of the CagriSema combination.